Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04152499
Title Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Klus Pharma Inc.
Indications

pancreatic adenocarcinoma

urinary bladder cancer

triple-receptor negative breast cancer

gastric adenocarcinoma

ovary epithelial cancer

Therapies

SKB264

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California Los Angeles Recruiting Los Angeles California 90404 United States Details
Georgetown University Recruiting Washington District of Columbia 20057 United States Details
Florida Cancer Specialists and Research Institute Recruiting Sarasota Florida 34232 United States Details
Beth Israel Deaconess Medical Center Recruiting Boston Massachusetts 02215 United States Details
START MidWest Recruiting Grand Rapids Michigan 49546 United States Details
The University of Oklahoma Health Sciences Center Recruiting Oklahoma City Oklahoma 73104 United States Details
Providence Cancer Institute, Franz Clinic Recruiting Portland Oregon 97213 United States Details
Mary Crowley Cancer Research Recruiting Dallas Texas 75230 United States Details
MD Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
Virginia Cancer Specialists Recruiting Fairfax Virginia 22031 United States Details
Shanghai East Hospital Recruiting Shanghai China Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field